IntegraGen Inkomsten in het verleden

Verleden criteriumcontroles 0/6

IntegraGen has been growing earnings at an average annual rate of 48.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 13.4% per year.

Belangrijke informatie

48.1%

Groei van de winst

45.9%

Groei van de winst per aandeel

Biotechs Groei van de industrie30.8%
Inkomstengroei13.4%
Rendement op eigen vermogen-8.5%
Nettomarge-1.4%
Laatste winstupdate31 Dec 2023

Recente prestatie-updates uit het verleden

Recent updates

Lacklustre Performance Is Driving IntegraGen SA's (EPA:ALINT) Low P/S

Aug 28
Lacklustre Performance Is Driving IntegraGen SA's (EPA:ALINT) Low P/S

There's No Escaping IntegraGen SA's (EPA:ALINT) Muted Revenues

Feb 17
There's No Escaping IntegraGen SA's (EPA:ALINT) Muted Revenues

Pinning Down IntegraGen SA's (EPA:ALINT) P/E Is Difficult Right Now

Apr 19
Pinning Down IntegraGen SA's (EPA:ALINT) P/E Is Difficult Right Now

Opbrengsten en kosten

Hoe IntegraGen geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

ENXTPA:ALINT Opbrengsten, kosten en inkomsten (EUR Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
31 Dec 2313050
30 Sep 2313050
30 Jun 2313050
31 Mar 2313050
31 Dec 2213050
30 Sep 2213030
30 Jun 2213000
31 Mar 2212000
31 Dec 2111000
30 Sep 2110030
30 Jun 219-160
31 Mar 219-160
31 Dec 209060
30 Sep 209060
30 Jun 209060
31 Mar 209060
31 Dec 198060
30 Sep 198-140
30 Jun 197-130
31 Mar 197-130
31 Dec 187-130
30 Sep 187-130
30 Jun 187-130
31 Mar 187-130
31 Dec 177-130
30 Sep 176-140
30 Jun 177-130
31 Mar 176-130
31 Dec 166-230
30 Sep 166-230
30 Jun 166-230
31 Mar 166-230
31 Dec 156-230
30 Sep 156-130
30 Jun 156-130
31 Mar 156-130
31 Dec 146-130
30 Sep 146-130
30 Jun 145-230
31 Mar 145-230
31 Dec 135-330

Kwaliteitswinsten: ALINT is currently unprofitable.

Groeiende winstmarge: ALINT is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: ALINT is unprofitable, but has reduced losses over the past 5 years at a rate of 48.1% per year.

Versnelling van de groei: Unable to compare ALINT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: ALINT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Rendement op eigen vermogen

Hoge ROE: ALINT has a negative Return on Equity (-8.52%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden